The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects
Open accessAbstract
The purpose of this paper is to establish the pharmacokinetics and safety of escalating, once-daily doses of daptomycin, a novel lipopeptide antibiotic active against gram-positive pathogens, including those resistant to methicillin and vancomycin. This phase 1, multiple-dose, double-blind study involved 24 healthy subjects in three dose cohorts (4, 6, and 8 mg/kg of body weight) who were randomized to receive daptomycin or the control at a 3:1 ratio and administered the study medication by a 30-min intravenous infusion every 24 h for 7 to 14 days. Daptomycin pharmacokinetics was assessed by blood and urine sampling. Safety and tolerability were evaluated by monitoring adverse events (AEs) and laboratory parameters. Daptomycin pharmacokinetics was linear through 6 mg/kg, with a slight (∼20%) nonlinearity in the area under the curve and trough concentration at the highest dose studied (8 mg/kg). The pharmacokinetic parameters measured on the median day of the study period, (day 7) were half-life (∼9 h), volume of distribution (∼0.1 liters/kg), systemic clearance (∼8.2 ml/h/kg), and percentage of the drug excreted intact in urine from 0 to 24 h (∼54%). Daptomycin protein binding (mean amount bound, 91.7%) was independent of the drug concentration. No gender effect was observed. All subjects who received daptomycin completed the study. The frequencies and distributions of treatment-emergent AEs were similar for the subjects who received daptomycin and the control subjects. There were no serious AEs and no pattern of dose-related events. The pharmacokinetics of once-daily administration of daptomycin was linear through 6 mg/kg. For all three doses, plasma daptomycin concentrations were consistent and predictable throughout the dosing interval. Daptomycin was well tolerated when it was administered once daily at a dose as high as 8 mg/kg for 14 days.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Rybak, M. J., Hershberger, E., Moldovan, T., & Grucz, R. G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1062-1066.2000 · Cited by 362
Delayed onset muscle soreness following repeated bouts of downhill running
Byrnes, W. C., Clarkson, P. M., White, J. S., Hsieh, S. S., Frykman, P. N., & Maughan, R. J. (1985) · Journal of Applied Physiology · doi:10.1152/jappl.1985.59.3.710 · Cited by 330
Daptomycin: a novel agent for Gram-positive infections
Tally, F. P., Zeckel, M., Wasilewski, M. M., Carini, C., Berman, C. L., Drusano, G. L., & Oleson JR, F. B. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.8.1223 · Cited by 205
Once-Daily Dosing in Dogs Optimizes Daptomycin Safety
Oleson, F. B., Berman, C. L., Kirkpatrick, J. B., Regan, K. S., Lai, J.-J., & Tally, F. P. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.2948-2953.2000 · Cited by 196
Cassell, G. H. (2001) · JAMA · doi:10.1001/jama.285.5.601 · Cited by 162
Woodworth, J. R., Nyhart, E. H., Brier, G. L., Wolny, J. D., & Black, H. R. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.318 · Cited by 155
Hanberger, H., Nilsson, L. E., Maller, R. K., et al. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.9.1710 · Cited by 139
Lamp, K. C., Rybak, M. J., Bailey, E. M., & Kaatz, G. W. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2709 · Cited by 131
Lakey, J. H., & Ptak, M. (1988) · Biochemistry · doi:10.1021/bi00413a009 · Cited by 130
Snydman, D. R., Jacobus, N. V., McDermott, L. A., Lonks, J. R., & Boyce, J. M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3447-3450.2000 · Cited by 101
Louie, A., Baltch, A. L., Ritz, W. J., Smith, R. P., & Asperilla, M. O. (2009) · Chemotherapy · doi:10.1159/000239141 · Cited by 27
Vance‐Bryan, K., Larson, T. A., Rotschafer, J. C., & Toscano, J. P. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.10.2334 · Cited by 24
Cited by
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Self-citationEffect of tolerance on the evolution of antibiotic resistance under drug combinations
Liu, J., Gefen, O., Ronin, I., Bar-Meir, M., & Balaban, N. Q. (2020) · Science · doi:10.1126/science.aay3041 · Cited by 485
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
Ulldemolins, M., Roberts, J. A., Rello, J., Paterson, D. L., & Lipman, J. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539220-000000000-00000 · Cited by 469
“The authors compared data from burns patients with data from healthy subjects([46]) and noted Cmax and AUC24 values in the burns patients that were nearly half those observed in the healthy subjects.”
ResultReview: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs)
Dijksteel, G. S., Ulrich, M. M. W., Middelkoop, E., & Boekema, B. K. H. L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.616979 · Cited by 428
Carpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358
Metadata
- Authors
- Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-04
- Volume
- 47
- Issue
- 4
- Pages
- 1318-1323
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2139155301
- Cited by
- 358
- References
- 13
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.